calculation of 90% CI for continuous variable in clinical endpoint studies [General Sta­tis­tics]

posted by DavidManteigas – Portugal, 2017-11-21 11:01 (2319 d 22:43 ago) – Posting: # 17996
Views: 4,723

Hi GM,

As El Maestro explained, when your test hypothesis is a ratio (multiplicative model) then you must work with ln transformed data. The guidance is clear on that as it also defines the acceptance range as 0.8 to 1.25 (multiplicative model). If in some guideline they state the hypothesis as treatment differences (H0: u1-u2=0) and a symmetric equivalence range (0.8 to 1.2) then they would be suggesting an analysis on untransformed data. This is true regardless of the type of your endpoint as long as it is a continuous endpoint. As simple as that ;-)

Regards,
David

Complete thread:

UA Flag
Activity
 Admin contact
22,957 posts in 4,819 threads, 1,636 registered users;
118 visitors (0 registered, 118 guests [including 7 identified bots]).
Forum time: 09:45 CET (Europe/Vienna)

With four parameters I can fit an elephant,
and with five I can make him wiggle his trunk.    John von Neumann

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5